Navigation Links
Human Genome Sciences Begins Delivery of First-in-Class Anthrax Treatment to U.S. Strategic National Stockpile
Date:2/2/2009

cs License Application (BLA) with the FDA in the second quarter of 2009. HGS will receive an additional $15 million from the U.S. Government upon FDA licensure of ABthrax.

About Human Genome Sciences

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs. The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax and cancer. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing. ABthrax(TM) (raxibacumab) is in late-stage development for inhalation anthrax, and HGS also has three drugs in clinical development for the treatment of cancer, including two TRAIL receptor antibodies and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to certain products in the GSK clinical pipeline including darapladib, which GSK has advanced to Phase 3 development as a potential treatment for coronary heart disease.

For more information about HGS, please visit the Company's web site at www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

For an Electronic Press Kit on this announcement, please click here: http://www.firstlinemedia.com/epk/hgs/.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B ar
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Mardil Inc. Advances Its Novel Cardiac Device to First-In-Human Trials for Mitral Valve Regurgitation
2. Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
3. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
4. Cequent to Present First Proof of Activity of an Oral RNAi Drug in Non-Human Primates at February Keystone Conference
5. 2008 Human Research Protection Award Recipients Announced
6. USD 12.5 m Funding for the Development of Intercells Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
7. Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
8. SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
9. GeoVaxs Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
10. Celladon Announces Presentation of Clinical Data From First-in-Human MYDICAR(R) Trial for Advanced Heart Failure at American Heart Association Scientific Sessions
11. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... DIEGO , Sept. 19, 2014  Lpath, ... leader in bioactive lipid-targeted therapeutics, announced today that ... 3,605,042 registered shares of common stock and 3,605,042 ... combined purchase price for one registered share of ... one unregistered share of common stock will be ...
(Date:9/19/2014)... and ORLANDO, Fla. , Sept. 19, ... therapy continues to grow, with the publication of two ... in Otolaryngology – Head and Neck Surgery ... worsening of both objective and subjective measures of sleep ... Inspire therapy for the reduction in obstructive sleep apnea ...
(Date:9/19/2014)... 2014  Over 200 runners participated in the fifth ... Radiation Oncology Institute (ROI), hosted by Radiation Business Solutions. This ... in San Francisco.  "Donations are still ... Radiation Business Solutions, "but at this point, through ... for the ROI this year. This surpasses last year,s ...
Breaking Medicine Technology:Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3
... Rochester Medical Corporation (Nasdaq: ROCM ) today announced that it is ... healthcare alliance. , , , ... with more than 800 suppliers and Rochester Medical is one of 38 ... outstanding management of Premier agreements and drive toward the mutual goal of ...
... June 22 Hospira, Inc. (NYSE: HSP ... it has received U.S. Food and Drug Administration (FDA) approval ... g vials.  The medication, a carbapenem that belongs to the ... Merrem® I.V. Sales of the name-brand product in ...
Cached Medicine Technology:Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance 2Rochester Medical Corporation Honored by Premier Healthcare Alliance for Exceptional Supplier Performance 3Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.) 2Hospira Receives FDA Approval for Meropenem for Injection, USP (I.V.) 3
(Date:9/20/2014)... 20, 2014 Ticket Down is ... . This popular ticket exchange is offering their customer ... The 2015 schedule of tours is beginning to fill up. ... their plans to hit the road, including 21-year-old pop superstar, ... the “Honeymoon Tour,” which will take her to 25 cities ...
(Date:9/20/2014)... 20, 2014 On Monday, September 22, ... pediatric cancer research grant from Hyundai Hope on Wheels ... Children’s Hospital located on 11234 Anderson St., in Loma ... Kimberley Payne, Associate Professor at Loma Linda University and ... leukemia in children. , Loma Linda University ...
(Date:9/20/2014)... 20, 2014 The print component ... edition of the Calgary Herald, with a circulation ... of 270,000. The digital component is distributed nationally ... a network of top news sites and partner ... campaign, visit http://www.worklifebalanceinfo.ca . , The publication ...
(Date:9/20/2014)... -- The avian flu that killed 160 harbor seals ... respiratory drops and therefore poses a potential threat to ... human illnesses have been linked to the harbor seal ... discovered natural mutations to the avian H3N8 seal virus ... in droplets. Current seasonal flu vaccines wouldn,t help ...
(Date:9/20/2014)... season is coming soon. The high-end fashion designer BellasDress is ... . A lot of sophisticated women like its new items. ... for its high quality clothes. Now, each of its elegant ... 71 percent off. , The company’s cocktail dress assortment ... many fashionable colors. Mary, the company’s sales manager, believes that ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 2Health News:Ariana Grande Tickets in Phoenix, Los Angeles, Anaheim, San Jose, Seattle, and Vancouver Go on Sale Today 3Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 2Health News:Loma Linda University Medical Center Receives $250,000 Research Grant From Hyundai Hope On Wheels In Honor Of National Childhood Cancer Awareness Month 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:Avian Flu In Harbor Seals Could Infect People 2Health News:High-end Fashion Designer BellasDress Offers Luxurious Cocktail Dresses For Sophisticated Women 2
... Commitment to Active Listening , ROCHESTER, ... Tomaino specializes in cutting-edge shoulder procedures including everything ... a reversed shoulder replacement that relieves pain, restores ... is also adept at the practice of active ...
... another reason for people to watch their blood pressure, ... that increased blood pressure in older adults is directly ... already high blood pressure. This means that stressful situations ... think clearly. , Dr. Jason Allaire, an assistant professor ...
... LONDON, Dec. 15 The immunoassay diagnostics market is ... It is being challenged by a number of factors ... the heightened popularity of molecular tests in areas like ... propelling companies to develop novel assays and differentiate themselves ...
... Dec. 15 Roche announced today that its,innovative ... allowing,it to be sold for clinical use in ... Test, v2.0 utilizes a unique design to,simultaneously amplify ... genome.,This approach provides reliable test results even when ...
... possible new therapeutic target for pancreatic cancer, the most ... the proteins whose DNA recipe comes from gene, "Seven-In-Absentia," ... Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in ... fruit fly, Drosophila melanogaster, at the Mayo Clinic College ...
... featured in an upcoming episode. , ... Deerfield Beach, FL (PRWEB) December ... announce that Gradient Medical, LLC will be featured in an upcoming episode ... Today., , ,Pain is a national public healthcare crisis. It is estimated ...
Cached Medicine News:Health News:Rochester Shoulder Surgeon Blends Innovative Techniques with Personalized Patient Care 2Health News:Rochester Shoulder Surgeon Blends Innovative Techniques with Personalized Patient Care 3Health News:Rochester Shoulder Surgeon Blends Innovative Techniques with Personalized Patient Care 4Health News:Development of Novel Assays Vital for the European Immunoassay Diagnostics Market 2Health News:Development of Novel Assays Vital for the European Immunoassay Diagnostics Market 3Health News:New Roche Dual Target HIV-1 Test Approved for Use in European Union 2Health News:New Roche Dual Target HIV-1 Test Approved for Use in European Union 3Health News:Blocking molecular pathway with whimsical name possible therapeutic target for pancreatic cancer 2Health News:"The Economic Report" Show to Feature Gradient Medical, LLC 2
Thru cut kerrison style punch 30 deg, 2.75 X 1.4 mm cut, 110 working length....
6 mm, 45 degree upwards, detachable....
Aaron 2250 is a multipurpose electrosurgical generator with monoploar and bi-polar functions....
Sabre 180 is a powerful niche generator....
Medicine Products: